Is Mitotane a cancer cell's favorite?

Mitotane(Mitotane) is an antineoplastic drug specifically used for adrenocortical carcinoma (ACC; adrenal carcinoma) with selective toxic effects. People often misunderstand that it is "the favorite drug of cancer cells". In fact, this statement is not accurate. The main mechanism of mitotane is to disrupt the metabolism and hormone secretion functions of adrenocortical cancer cells, hinder tumor cell proliferation, and induce cancer cell apoptosis. Its effect is highly targeted, so it plays a significant role in the treatment of ACC, but has limited impact on other types of tumors or normal cells.

Adrenocortical cancer is a rare and highly malignant endocrine tumor. Some patients produce excess cortisol or other hormones, leading to symptoms such as Cushing's syndrome, hypertension, and diabetes. Mitotane not only inhibits cancer cell growth but also regulates hormone levels, thereby improving patients' symptoms and quality of life. It inhibits the mitochondrial function and lipid metabolism of adrenal cells, making the tumor cell environment unfavorable for survival. This kind of targeting and selectivity is not available in other conventional chemotherapy drugs.

In clinical application, mitotane is often used in patients with ACC that cannot be surgically removed or have a high risk of postoperative recurrence to help delay disease progression. Doctors will accurately adjust the dosage based on the patient's weight, tumor type, hormone levels and blood drug concentration monitoring results to ensure that the drug is both effective and safe. Long-term follow-up and regular monitoring are important aspects of successful mitotane treatment, because too low a plasma concentration may reduce efficacy, while too high a concentration may increase the risk of adverse reactions.

Although mitotane is highly sensitive toACC cells, it is not the "favorite drug" of all cancer cells. Its advantage lies in its selectivity and targeting of ACC, which can specifically interfere with the proliferation and hormone secretion of adrenocortical cancer cells, but has limited effect on other types of cancer cells.

Reference materials:https://go.drugbank.com/drugs/DB00648